Beyond the Guidelines: Treatment of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis

被引:2
|
作者
Tompkins, Madeline G. [1 ]
Pettit, Rebecca [1 ]
机构
[1] Indiana Univ Hlth, Riley Hosp Children, Indianapolis, IN USA
关键词
cystic fibrosis; corticosteroids; pulmonary; antifungals; biopharmaceutics; ANTI-IGE ANTIBODY; OMALIZUMAB TREATMENT; THERAPY; POSACONAZOLE; PATIENT; ABPA; BENRALIZUMAB; AMPHOTERICIN; MANAGEMENT; CHILDREN;
D O I
10.1177/10600280211022065
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To review the available literature addressing alternative allergic bronchopulmonary aspergillosis (ABPA) treatment options for patients with cystic fibrosis (CF). Data Sources: A literature search of PubMed was performed (January 2002 to April 2021) using the following search terms: allergic bronchopulmonary aspergillosis, aspergillus-related lung disease, cystic fibrosis. Manufacturer prescribing information, clinical practice guidelines, and data from ClinicalTrials.gov were incorporated in the reviewed data. Study Selection and Data Extraction: Relevant English-language studies or those conducted in humans were considered for inclusion. Data Synthesis: Available literature for alternative ABPA treatments in CF is lacking randomized controlled trials, but there is considerable support in case reports and case series describing the benefits in pediatric and adult patients. Recent literature has begun to explore the place in therapy for novel, corticosteroid-sparing treatment approaches. The alternative therapies summarized in this review all resulted in clinical improvement and subsequent discontinuation or dose reductions of oral corticosteroids, with minimal reported adverse drug effects. Relevance to Patient Care and Clinical Practice: Although corticosteroids are the cornerstone of ABPA management, the toxicities can be significant limitations in an already high-risk patient population. Patients may fail or become intolerant to guideline-recommended therapies and require alternative treatment approaches. Conclusions: Alternative treatment modalities for ABPA in patients with CF, including azole antifungals, pulsed intravenous glucocorticoids, omalizumab, mepolizumab, and inhaled amphotericin, appear to be efficacious and well tolerated. Pharmacological properties including route of administration, storage and stability, beyond use dating, and adverse effects of the various treatment modalities must be considered when selecting a practical care plan for patients.
引用
收藏
页码:181 / 192
页数:12
相关论文
共 50 条
  • [21] Omalizumab treatment for allergic bronchopulmonary aspergillosis in young patients with cystic fibrosis
    Perisson, Caroline
    Destruys, Leila
    Grenet, Dominique
    Bassinet, Laurence
    Derelle, Jocelyne
    Sermet-Gaudelus, Isabelle
    Thumerelle, Caroline
    Prevotat, Anne
    Rosner, Vincent
    Clement, Annick
    Corvol, Harriet
    RESPIRATORY MEDICINE, 2017, 133 : 12 - 15
  • [22] Allergic bronchopulmonary aspergillosis in paediatric cystic fibrosis patients
    de Almeida, Marina Buarque
    Bussamra, Maria Helena F.
    Rodrigues, Joaquim Carlos
    PAEDIATRIC RESPIRATORY REVIEWS, 2006, 7 (01) : 67 - 72
  • [23] Allergic bronchopulmonary aspergillosis in two patients with cystic fibrosis
    Anadol, D
    Özçelik, U
    Kiper, N
    Göçmen, A
    TURKISH JOURNAL OF PEDIATRICS, 2000, 42 (01) : 68 - 71
  • [24] Diagnosis of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis
    Skov, M
    Koch, C
    Reimert, CM
    Poulsen, LK
    ALLERGY, 2000, 55 (01) : 50 - 58
  • [25] Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosis
    Moss, Richard B.
    CURRENT OPINION IN PULMONARY MEDICINE, 2010, 16 (06) : 598 - 603
  • [26] Allergic bronchopulmonary aspergillosis without asthma or cystic fibrosis
    Kaur, Parminder
    Kumar, Pankaj
    Randev, Shivani
    Guglani, Vishal
    PAEDIATRICS AND INTERNATIONAL CHILD HEALTH, 2020, 40 (03) : 199 - 201
  • [27] Role of omalizumab in the management of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis
    Delgado Pecellin, Isabel
    Quintana Gallego, Esther
    Pedregal Solano, Celeste
    Calero Acuna, Carmen
    MEDICINA CLINICA, 2015, 144 (04): : 190 - 191
  • [28] Allergic bronchopulmonary aspergillosis in cystic fibrosis - Role of atopy and response to itraconazole
    Nepomuceno, IB
    Esrig, S
    Moss, RB
    CHEST, 1999, 115 (02) : 364 - 370
  • [29] Pulse intravenous methylprednisolone for resistant allergic bronchopulmonary aspergillosis in cystic fibrosis
    Thomson, JM
    Wesley, A
    Byrnes, CA
    Nixon, GM
    PEDIATRIC PULMONOLOGY, 2006, 41 (02) : 164 - 170
  • [30] VARIABILITY IN PARAMETERS OF ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS IN PATIENTS WITH CYSTIC-FIBROSIS
    HUTCHESON, PS
    REJENT, AJ
    SLAVIN, RG
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1991, 88 (03) : 390 - 394